Insights Into the Emerging Role of Baf53b in Autism Spectrum Disorder.
BAF53B mutations can derail synapse building and produce autism-like traits, but the work is still at the lab bench.
01Research in Context
What this study did
MFarley et al. (2022) wrote a narrative review. They pulled together papers on a gene called BAF53B.
They looked at human cases and mouse models. Both showed links between BAF53B glitches and autism traits.
What they found
Mutations in BAF53B mess up how brain cells turn genes on and off. This hurts synapse growth.
The same mutations show up in some people with autism and intellectual disability. Mice with these changes act autistic.
How this fits with other research
Ch'ng et al. (2015) ran a giant meta-analysis of brain gene data. They also saw mitochondrial genes out of step, matching the energy-hungry synapse idea in ME et al.
Wang et al. (2025) later looked for early biomarkers. They said none are ready for clinic use, so keep using behavioral tests. ME et al. agree: BAF53B tests stay in the lab for now.
Brondino et al. (2016) reviewed GABA drugs for autism and found no clear benefit. BAF53B controls GABA signaling too, so the lack of drug effect makes sense until we fix the root wiring.
Why it matters
You will not order a BAF53B scan next week. Still, the review reminds us that some autism cases rest on hidden wiring problems, not poor parenting or bad ABA. When progress is slow, think medical referral. Genetic counselors can update families. For now, keep running strong behavioral programs while science looks for ways to protect or regrow synapses.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →If a client stalls despite solid ABA, suggest the family ask their doctor about genetic counseling.
02At a glance
03Original abstract
Accurate and precise regulation of gene expression is necessary to ensure proper brain development and plasticity across the lifespan. As an ATP-dependent chromatin-remodeling complex, the BAF (Brg1 Associated Factor) complex can alter histone-DNA interactions, facilitating dynamic changes in gene expression by controlling DNA accessibility to the transcriptional machinery. Mutations in 12 of the potential 29 subunit genes that compose the BAF nucleosome remodeling complex have been identified in several developmental disorders including Autism spectrum disorders (ASD) and intellectual disability. A novel, neuronal version of BAF (nBAF) has emerged as promising candidate in the development of ASD as its expression is tied to neuron differentiation and it's hypothesized to coordinate expression of synaptic genes across brain development. Recently, mutations in BAF53B, one of the neuron specific subunits of the nBAF complex, have been identified in patients with ASD and Developmental and epileptic encephalopathy-76 (DEE76), indicating BAF53B is essential for proper brain development. Recent work in cultured neurons derived from patients with BAF53B mutations suggests links between loss of nBAF function and neuronal dendritic spine formation. Deletion of one or both copies of mouse Baf53b disrupts dendritic spine development, alters actin dynamics and results in fewer synapses <i>in vitro.</i> In the mouse, heterozygous loss of Baf53b severely impacts synaptic plasticity and long-term memory that is reversible with reintroduction of Baf53b or manipulations of the synaptic plasticity machinery. Furthermore, surviving Baf53b-null mice display ASD-related behaviors, including social impairments and repetitive behaviors. This review summarizes the emerging evidence linking deleterious variants of BAF53B identified in human neurodevelopmental disorders to abnormal transcriptional regulation that produces aberrant synapse development and behavior.
, 2022 · doi:10.3389/fnmol.2022.805158